The journey of CAR-T therapy in hematological malignancies

The journey of CAR-T therapy in hematological malignancies

Abstract Chimeric antigen receptor T (CAR-T) cells therapy has revolutionized the treatment paradigms for hematological malignancies, with multi-line therapy-refractory patients achieving durable complete remissions (CR) and relatively high objective response rate (ORR). So far, many CAR-T products,...

Full description

Bibliographic Details
Main Authors: Junru Lu, Guan Jiang
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Molecular Cancer
Subjects:
CAR-T cell therapy
Hematological malignancies
Targeted therapy
Combinatorial therapy
Drug product
Online Access:https://doi.org/10.1186/s12943-022-01663-0

Internet

https://doi.org/10.1186/s12943-022-01663-0

Similar Items